TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30020511

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM-I)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control
Number of subjects: 342
Study: 29296811

Group type: EXPERIMENTAL
Intervention: Regadenoson (1.44 μg/kg per hour)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 92
Study: 25574111

Group type: EXPERIMENTAL
Intervention: Clarithromycin-based triple therapy (PAC group: rabeprazole, amoxicillin, clarithromycin)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Metronidazole-based triple therapy (PAM group: rabeprazole, amoxicillin, metronidazole)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole and amoxicillin followed by rabeprazole, clarithromycin and metronidazole)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (rabeprazole, amoxicillin, clarithromycin and metronidazole)
Number of subjects: 680
Study: 23548622

Group type: EXPERIMENTAL
Intervention: Subconjunctival sirolimus (440 μg) administered every 3 months for 24 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Fellow eyes (untreated controls)
Number of subjects: 11
Study: 21972580

Group type: EXPERIMENTAL
Intervention: Intensified mouth care protocol (6 sessions per day including 2 teeth brushings and 4 sessions with chlorhexidine 0.12%)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard mouth care protocol (3 sessions per day including chlorhexidine 0.12%)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intensified mouth care protocol
Number of subjects: 182
Study: 19834019

Group type: EXPERIMENTAL
Intervention: Microplasmin 2 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microplasmin 3 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microplasmin 4 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16675781

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Ethambutol
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 336
Study: 14726080

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 40
Study: 11041197

Group type: EXPERIMENTAL
Intervention: Lateral slide exercise incorporated into home exercise program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no lateral slide exercise)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (lateral slide exercise and control)
Number of subjects: 14
Study: 9250760

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluorapatite (FA) coating
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both coatings
Number of subjects: 15
Study: 8350466

Group type: COMPARATOR
Intervention: 0 gamma of PGE1
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.005 gamma of PGE1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.02 gamma of PGE1
Number of subjects: 36
Study: 3551606

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30348113

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 27080806

Group type: EXPERIMENTAL
Intervention: Play distraction (storytelling, pictures, and colouring activities)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Pharmacological premedication
Number of subjects: 168
Study: 24929548

Group type: EXPERIMENTAL
Intervention: Video-assisted oral debriefing (VAOD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral debriefing alone (ODA)
Number of subjects: 48
Study: 22037722

Group type: EXPERIMENTAL
Intervention: Topical suspension of bacterial antigens (Lantigen B)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 20338560

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy treatment on days 8 or/and 11 to 13 of the menstrual cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no biopsy treatment)
Number of subjects: 0
Study: 18669897

Group type: EXPERIMENTAL
Intervention: Ordinal statistical tests (e.g., bootstrapping the difference in mean rank, Mann‐Whitney U test, ordinal logistic regression)
Number of subjects: 335305

Group type: EXPERIMENTAL
Intervention: Ordinal statistical tests
Number of subjects: 335305
Study: 15866563

Group type: EXPERIMENTAL
Intervention: Yohimbine (higher dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12784833

Group type: EXPERIMENTAL
Intervention: Directed forgetting task with instructions to remember or forget neutral and emotional words.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Implicit memory assessment across states.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Memory recall assessment for emotional vs neutral information.
Number of subjects: 12
Study: 10505914

Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules
Number of subjects: 761

Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 761
Study: 8721637

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (5 to 10 microg/kg/min)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thallium-201 SPECT with reinjection
Number of subjects: 45
Study: 1781563

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.4 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.5 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nasal midazolam (0.2 mg/kg)
Number of subjects: 90
Study: 6764827

Group type: EXPERIMENTAL
Intervention: BCG vaccinated group
Number of subjects: 54239

Group type: EXPERIMENTAL
Intervention: vole‐bacillus vaccinated group
Number of subjects: 54239

Group type: COMPARATOR
Intervention: randomly‐allocated unvaccinated (control) group
Number of subjects: 54239
Study: 31903505

Group type: EXPERIMENTAL
Intervention: Clear aligners (Invisalign)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fixed appliances (Victory Series)
Number of subjects: 70
Study: 30727929

Group type: EXPERIMENTAL
Intervention: Herbal compound (one sachet twice daily for 12 weeks) containing 300 mg Aloe vera, 1.8 g black seed, 300 mg garlic, 2.5 g fenugreek seed, 1 g psyllium seed, 500 mg milk thistle seed
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy with hypolipidemic and hypoglycemic drugs
Number of subjects: 50
Study: 27908974

Group type: EXPERIMENTAL
Intervention: Humor therapy program
Number of subjects: 306

Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 306
Study: 25295681

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with selected nutraceuticals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22849318

Group type: EXPERIMENTAL
Intervention: Experimental cheese (from cows fed a grass and maize silage‐based diet with 5% of linseed oil added)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cheese (without linseed oil)
Number of subjects: 0
Study: 21658122

Group type: EXPERIMENTAL
Intervention: Nordic walking (5 hours per week for 4 months)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (maintained unaltered habitual lifestyle)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study: 19458434

Group type: EXPERIMENTAL
Intervention: Early cranioplasty
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Late cranioplasty
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy volunteers (reference standard)
Number of subjects: 26
Study: 16737369

Group type: EXPERIMENTAL
Intervention: Social category primes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Response behavior primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social category primes with differentiation mind-set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social category primes with similarity mind-set
Number of subjects: 0
Study: 14962397

Group type: EXPERIMENTAL
Intervention: Articulatory suppression condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no dual-task) condition
Number of subjects: 0
Study: 11701403

Group type: EXPERIMENTAL
Intervention: Polyurethane encasings impermeable to particles > 3 mum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cotton encasings
Number of subjects: 0
Study: 9002118

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 10 mg/kg every 8 h for 7 days followed by oral ciprofloxacin 20 mg/kg every 12 h for a minimum of 3 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ceftazidime 50 mg/kg every 8 h plus tobramycin 3 mg/kg every 8 h for a minimum of 10 days
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both treatment groups (ciprofloxacin and ceftazidime/tobramycin)
Number of subjects: 130
Study: 8299664

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2436183

Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation (CCS) using the Neurolith 601 stimulator, with ON-OFF switching controlled by a magnetically controllable switch, duration of stimulation was four months after surgery.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Chronic cerebellar stimulation (CCS)
Number of subjects: 33
Study: 30043517

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 0
Study: 26454361

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once a week
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 4 weeks
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 25605628

Group type: EXPERIMENTAL
Intervention: Transhiatal (TH) approach
Number of subjects: 167

Group type: COMPARATOR
Intervention: Left thoracoabdominal (LTA) approach
Number of subjects: 167
Study: 23580011

Group type: EXPERIMENTAL
Intervention: Long-term oral contraceptives (OCs) therapy with different progestins (desogestrel, gestodene, dienogest)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (patients who refused postoperative hormonal therapy)
Number of subjects: 168
Study: 20307355

Group type: EXPERIMENTAL
Intervention: 40 g alpha-lactalbumin (LAC; l-tryptophan (Trp):large neutral amino acids (LNAA) ratio of 7.6)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 40 g casein (placebo; Trp:LNAA ratio of 4.0)
Number of subjects: 25
Study: 18262575

Group type: EXPERIMENTAL
Intervention: 0.3 M sucrose solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sweet flavours (orange juice, coke, lemonade)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.15 M NaCl solution (unpleasant stimulus)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evian mineral water (neutral stimulus)
Number of subjects: 20
Study: 16792438

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1000
Study: 12792136

Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: timolol
Number of subjects: 34
Study: 11235004

Group type: EXPERIMENTAL
Intervention: Aerobic conditioning program (24 women)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No sports activity (10 women)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 34
Study: 8639883

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) 10,000 U/d subcutaneously 7 days a week (fixed dose group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: rhEPO 2,000 U/d subcutaneously for 8 weeks followed by step‐wise escalation of the rhEPO dose (titration group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: no rhEPO therapy (control group)
Number of subjects: 121
Study: 1598788

Group type: EXPERIMENTAL
Intervention: Single dose of 2 x 10(9) live bacteria
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Three doses every other day of 2 x 10(9) live bacteria
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Booster dose of 2 x 10(9) bacteria
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Three doses of the vaccine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Previous exposure to shigellae
Number of subjects: 21
Study: 6529523

Group type: EXPERIMENTAL
Intervention: Tiapamil (450 mg single oral dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiapamil (450 mg twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30446783

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Whole cohort (ET and APM combined)
Number of subjects: 107
Study: 30205493

Group type: EXPERIMENTAL
Intervention: High fructose meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low fructose meal
Number of subjects: 16
Study: 26993628

Group type: EXPERIMENTAL
Intervention: Quilizumab (300 mg monthly)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Quilizumab (monthly or quarterly dosing)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 578
Study: 25276983

Group type: EXPERIMENTAL
Intervention: Xingnaojing Injection combined with minimally invasive percutaneous drainage
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (minimally invasive percutaneous drainage only)
Number of subjects: 42
Study: 22742438

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy for 30 min every morning during chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy for 30 min every morning during chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy
Number of subjects: 39
Study: 19656432

Group type: EXPERIMENTAL
Intervention: Active rTMS to the left temporal cortex
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active rTMS to the right temporal cortex
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS to the vertex (control condition)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open continued treatment phase
Number of subjects: 18
Study: 17509068

Group type: EXPERIMENTAL
Intervention: Structured care (hospital outpatient clinic with initial 6 months' lifestyle programme followed by intensified pharmacological treatment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Structured care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensified pharmacological treatment (6-24 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (follow-up by general practitioner)
Number of subjects: 120
Study: 15843080

Group type: EXPERIMENTAL
Intervention: Rifaximin 800 mg/day for 10 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diet without milk for 40 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 32
Study: 11860405

Group type: EXPERIMENTAL
Intervention: 0.5 mg b.d. alosetron
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 mg b.d. alosetron
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10206459

Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen 1
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen 2
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not transfused before surgery)
Number of subjects: 118
Study: 7703878

Group type: EXPERIMENTAL
Intervention: Actively negotiated process of decision making (n = 53)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nonnegotiated approach (n = 45)
Number of subjects: 98
Study: 2720192

Group type: EXPERIMENTAL
Intervention: GUIDELINES (three sessions of advice using a pamphlet)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Manual (three sessions of instruction in the use of a 'self‐help' manual)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Therapist (six or more sessions of instruction in the methods outlined in the 'self‐help' manual)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall (1-year follow-up)
Number of subjects: 90
Study: 805651

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study: 31868791

Group type: EXPERIMENTAL
Intervention: Alternation flicker format
Number of subjects: 286

Group type: COMPARATOR
Intervention: Side-by-side layout
Number of subjects: 286

Group type: COMPARATOR
Intervention: Up-and-down layout
Number of subjects: 286
Study: 30924890

Group type: EXPERIMENTAL
Intervention: Individual counseling through a range of activities and home visits for a mean duration of 5.5 years
Number of subjects: 650

Group type: COMPARATOR
Intervention: No special services
Number of subjects: 650
Study: 27267614

Group type: EXPERIMENTAL
Intervention: Interleukin 2 receptor antagonist
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin induction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (low and high panel reactive antibody)
Number of subjects: 200
Study: 25686324

Group type: EXPERIMENTAL
Intervention: Group A (SRP + antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B (SRP followed by antibiotics: metronidazole 0.2 g tid for 7 days, amoxicillin 0.5 g tid for 7 days starting 1 day after SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group C (SRP alone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group A, Group B, Group C
Number of subjects: 30
Study: 21815995

Group type: EXPERIMENTAL
Intervention: Block bone grafts
Number of subjects: 15

Group type: COMPARATOR
Intervention: Particulate bone grafts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 15
Study: 21803755

Group type: EXPERIMENTAL
Intervention: Respiratory modulation (RM) device, 20 min sessions twice daily for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Music listening (ML) using a CD player, control group
Number of subjects: 72
Study: 19552750

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from a clinical pharmacist
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care from medical and nursing staff
Number of subjects: 240
Study: 16963348

Group type: EXPERIMENTAL
Intervention: Nutrition practice guidelines care (12 sites)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual nutrition care (13 sites)
Number of subjects: 215
Study: 15589864

Group type: EXPERIMENTAL
Intervention: 5 mg anastrozole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10 mg anastrozole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 15 mg anastrozole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg anastrozole
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: five daily doses of 10 mg or 15 mg anastrozole
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study: 12359281

Group type: EXPERIMENTAL
Intervention: IV 0.1 mg/Kg chlorpromazine (CPZ)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 9795928

Group type: EXPERIMENTAL
Intervention: Dexpanthenol nasal spray
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48
Study: 7900512

Group type: EXPERIMENTAL
Intervention: Diet low in fat and lactose
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 143
Study: 2468628

Group type: EXPERIMENTAL
Intervention: Oral information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slide-tape based information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Film-sound based information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overlap estimation
Number of subjects: 0
Study: 335490

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for four weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Inactive tablets (control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily
Number of subjects: 58
Study: 31278094

Group type: EXPERIMENTAL
Intervention: 1000 mg/day trans-resveratrol for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (methyl cellulose) for 8 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (trans-resveratrol and placebo)
Number of subjects: 72
Study: 28638702

Group type: EXPERIMENTAL
Intervention: 10 mg/day Rosuvastatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 mg/day Rosuvastatin
Number of subjects: 50
Study: 25781872

Group type: EXPERIMENTAL
Intervention: 1 minute rest interval (RI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 minute rest interval (RI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CNT)
Number of subjects: 30
Study: 23518825

Group type: EXPERIMENTAL
Intervention: Surgical group (tonsillectomy and/or adenoidectomy; n = 32)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonsurgical group (n = 76)
Number of subjects: 112